Skip to main content
Top
Published in: PharmacoEconomics 12/2014

01-12-2014 | Letter to the Editor

Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”

Author: Afschin Gandjour

Published in: PharmacoEconomics | Issue 12/2014

Login to get access

Excerpt

The article by Newall et al. [1] published recently in PharmacoEconomics presents a valuable summary of potential approaches of setting cost-effectiveness thresholds when facing scarce healthcare resources. One approach suggested by the World Health Organization (WHO) is to set cost-effectiveness thresholds according to gross domestic product (GDP). The article then discusses why these methods have not been used for the allocation of healthcare resources. The authors are right to point out that, beyond the criterion of cost-effectiveness, budget impact is of particular importance to decision makers. Yet, the WHO approach of setting a cost-effectiveness threshold does not adequately consider budget impact. In addition to cost-effectiveness and budget impact, there are other criteria (e.g. equity) that may also need to be considered. The particular focus of the article is low- and middle-income countries (LMICs), although in principle the ideas also apply to high-income countries (HICs). …
Literature
1.
go back to reference Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics. 2014;32(6):525–31.PubMedCrossRef Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics. 2014;32(6):525–31.PubMedCrossRef
2.
go back to reference Gandjour A. Germany’s decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules. Appl Health Econ Health Policy. 2011;9(2):65–71.PubMedCrossRef Gandjour A. Germany’s decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules. Appl Health Econ Health Policy. 2011;9(2):65–71.PubMedCrossRef
3.
go back to reference Gandjour A. Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule. Int J Health Plan Manage. 2014 May 1. Epub ahead of print. Gandjour A. Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule. Int J Health Plan Manage. 2014 May 1. Epub ahead of print.
4.
go back to reference Oeppen J, Vaupel JW. Demography. Broken limits to life expectancy. Science. 2002;296(5570):1029–31.PubMedCrossRef Oeppen J, Vaupel JW. Demography. Broken limits to life expectancy. Science. 2002;296(5570):1029–31.PubMedCrossRef
5.
go back to reference Torri T, Vaupel JW. Forecasting life expectancy in an international context. Int J Forecast. 2012;28(2):519–31.CrossRef Torri T, Vaupel JW. Forecasting life expectancy in an international context. Int J Forecast. 2012;28(2):519–31.CrossRef
7.
go back to reference Gandjour A, Gafni A. The German method for setting ceiling prices for drugs: in some cases less data are required. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):403–9.PubMedCrossRef Gandjour A, Gafni A. The German method for setting ceiling prices for drugs: in some cases less data are required. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):403–9.PubMedCrossRef
8.
go back to reference Institute for Quality and Efficiency in Health Care. Methods for assessment of the relation of benefits to costs in the German Statutory Health Care System—Version 1.0 (in German). Cologne: IQWiG; 2009. Institute for Quality and Efficiency in Health Care. Methods for assessment of the relation of benefits to costs in the German Statutory Health Care System—Version 1.0 (in German). Cologne: IQWiG; 2009.
9.
go back to reference Institute for Quality and Efficiency in Health Care. Documentation of comments on “Draft method for evaluating the relation between cost and benefit in the German Statutory Health Insurance System, version 2.0” (in German). Cologne: IQWiG; 2009. Institute for Quality and Efficiency in Health Care. Documentation of comments on “Draft method for evaluating the relation between cost and benefit in the German Statutory Health Insurance System, version 2.0” (in German). Cologne: IQWiG; 2009.
10.
go back to reference Jena AB, Philipson TJ. Cost-effectiveness analysis and innovation. J Health Econ. 2008;27(5):1224–36.PubMedCrossRef Jena AB, Philipson TJ. Cost-effectiveness analysis and innovation. J Health Econ. 2008;27(5):1224–36.PubMedCrossRef
Metadata
Title
Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”
Author
Afschin Gandjour
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 12/2014
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-014-0221-3

Other articles of this Issue 12/2014

PharmacoEconomics 12/2014 Go to the issue

Acknowledgement to Referees

Acknowledgements